Limits...
Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety

View Article: PubMed Central - PubMed

ABSTRACT

Background: The risk of getting influenza and pneumococcal disease is higher in cancer patients, and serum antibody levels tend to be lower in patients with hematological malignancy.

Objective: To assess flu and pneumococcal vaccinations efficacy, effectiveness, and safety in onco-hematological patients.

Methods: Two systematic reviews and possible meta-analysis were conducted to summarize the results of all primary study in the scientific literature about the flu and pneumococcal vaccine in onco-hematological patients. Literature searches were performed using Pub-Med and Scopus databases. StatsDirect 2.8.0 was used for the analysis.

Results: 22 and 26 studies were collected respectively for flu and pneumococcal vaccinations. Protection rate of booster dose was 30% (95% CI=6–62%) for H1N1. Pooled prevalence protection rate of H3N2 and B was available for meta-analysis only for first dose, 42.6% (95% CI=23.2 – 63.3 %) and 39.6 % (95% CI=26%–54.1%) for H3N2 and B, respectively. Response rate of booster dose resulted 35% (95% CI=19.7–51.2%) for H1N1, 23% (95% CI=16.6–31.5%) for H3N2, 29% (95% CI=21.3–37%) for B.

Conclusion: Despite the low rate of response, flu, and pneumococcal vaccines are worthwhile for patients with hematological malignancies. Patients undergoing chemotherapy in particular rituximab, splenectomy, transplant recipient had lower and impaired response. No serious adverse events were reported for both vaccines.

No MeSH data available.


Forrest plots of Response Rate stratify by serotype of vaccine (children) independently from the dose (first or booster). Response rate H1N1 children
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016013&req=5

f3-mjhid-8-1-e2016044: Forrest plots of Response Rate stratify by serotype of vaccine (children) independently from the dose (first or booster). Response rate H1N1 children

Mentions: Figure 3 showed the forest plot of the cohort studies focused on children setting. In relation to response rate in children, the pooled prevalence resulted in a value for H1N1 one dose of 59.3% (95% CI=46–71.9 %), Cochran Q=0.36 (df=1), p=0.546; for H3N2 a value of 50% (95% CI=36.8–63.2%), Cochran Q=2.87 (df=1), p=0.09; for B a value of 59.2% (95% CI=45.9–71.8%), Cochran Q=0.001 (df=1), p=0.9744. The all three were with fixed effect model.


Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety
Forrest plots of Response Rate stratify by serotype of vaccine (children) independently from the dose (first or booster). Response rate H1N1 children
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016013&req=5

f3-mjhid-8-1-e2016044: Forrest plots of Response Rate stratify by serotype of vaccine (children) independently from the dose (first or booster). Response rate H1N1 children
Mentions: Figure 3 showed the forest plot of the cohort studies focused on children setting. In relation to response rate in children, the pooled prevalence resulted in a value for H1N1 one dose of 59.3% (95% CI=46–71.9 %), Cochran Q=0.36 (df=1), p=0.546; for H3N2 a value of 50% (95% CI=36.8–63.2%), Cochran Q=2.87 (df=1), p=0.09; for B a value of 59.2% (95% CI=45.9–71.8%), Cochran Q=0.001 (df=1), p=0.9744. The all three were with fixed effect model.

View Article: PubMed Central - PubMed

ABSTRACT

Background: The risk of getting influenza and pneumococcal disease is higher in cancer patients, and serum antibody levels tend to be lower in patients with hematological malignancy.

Objective: To assess flu and pneumococcal vaccinations efficacy, effectiveness, and safety in onco-hematological patients.

Methods: Two systematic reviews and possible meta-analysis were conducted to summarize the results of all primary study in the scientific literature about the flu and pneumococcal vaccine in onco-hematological patients. Literature searches were performed using Pub-Med and Scopus databases. StatsDirect 2.8.0 was used for the analysis.

Results: 22 and 26 studies were collected respectively for flu and pneumococcal vaccinations. Protection rate of booster dose was 30% (95% CI=6–62%) for H1N1. Pooled prevalence protection rate of H3N2 and B was available for meta-analysis only for first dose, 42.6% (95% CI=23.2 – 63.3 %) and 39.6 % (95% CI=26%–54.1%) for H3N2 and B, respectively. Response rate of booster dose resulted 35% (95% CI=19.7–51.2%) for H1N1, 23% (95% CI=16.6–31.5%) for H3N2, 29% (95% CI=21.3–37%) for B.

Conclusion: Despite the low rate of response, flu, and pneumococcal vaccines are worthwhile for patients with hematological malignancies. Patients undergoing chemotherapy in particular rituximab, splenectomy, transplant recipient had lower and impaired response. No serious adverse events were reported for both vaccines.

No MeSH data available.